I will increase the base outsourcing facility user fee to a level set by HHS to support timely and regular FDA inspections.

Jim Banks · Indiana · Republican

spending impact 5.00 specificity 1.00 extraction confidence 85%

Contest this claim

Occurrences

Evidence

Section 5 amends 21 U.S.C. 379j-62(c)(1)(A)(i) by striking "$15,000" and inserting "a base amount deemed appropriate by the Secretary to fund activities to ensure the safety of compounded drug products." Section 4 also requires pre-compounding inspections and at least biennial reinspections for large-scale outsourcing facilities.

The introduced bill contains the promised fee increase and ties it to FDA oversight and inspections, but it is still only introduced legislation rather than enacted law.

partial later_term A for effort

S. 3794 Introduced in Senate (IS) - Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026
secondary · model gpt-5.4-mini · confidence 96%

Contest this evidence item

The Senate office’s legislation page still lists S.3794 with the latest action as "Read twice and referred to the Committee on Health, Education, Labor, and Pensions."

As of the latest official Senate office listing, the bill has not advanced beyond committee referral, so the promise remains unresolved as a policy outcome.

unresolved later_term

Legislation - Senator Jim Banks
secondary · model gpt-5.4-mini · confidence 82%

Contest this evidence item

Assessments

never later_term A for effort

Banks materially advanced legislation that would raise the outsourcing facility user fee to an HHS-set level and support regular FDA inspections, matching the promised mechanism. However, the bill has only been introduced and referred to committee, with no evidence that the fee increase was enacted or implemented. Because this was a serious legislative attempt but did not deliver the promised policy outcome, the correct rating is never with an effort badge.

provider codex_cli · model gpt-5.5 · confidence 90%